SELLAS launches $150M stock offering after Phase 3 cancer trial win
What's the deal? SELLAS Life SciencesDealroom has a profile for this one. Try Dealroom → Group, a late-stage clinical biopharmaceutical company, launched an underwritten public offering of $150 million in common stock on November 17. J.P. Morgan and TD Cowen are joint book-running managers, and SELLAS plans to grant underwriters a 30-day option to buy up to $22.5 million in additional shares.
Why now? The offering follows topline results from REGAL, the company's Phase 3 trial of galinpepimut-S (GPS) in acute myeloid leukemia. The trial met its primary overall survival endpoint, reporting median overall survival of 24 months versus 14.7 months for the best available treatment. SELLAS shares rose more than 281% after the news.
What's the endgame? SELLAS develops cancer therapies, led by GPS, which targets the WT1 protein found across many tumor types. The financing lets it convert the trial enthusiasm into capital for clinical development and potential regulatory preparations.
What could go wrong? The offering is proposed, not completed, and the final price and share count will determine its actual scale. Selling new shares dilutes existing holders, and the trial results remain topline — the investigational drug still faces regulatory review.
The signal: The raise adds to an already substantial funding runway. SELLAS also held an unused $150 million at-the-market equity facility, giving it two large potential sources of equity capital as it moves GPS toward regulators.
Read more: tokenpost.com
Image credit: "Chanelle Case Borden" by History at NIH, public domain (Public Domain Mark 1.0)